Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 16/20 | 0.93 |
| ▸ | SLC5A1 | P13866 | 12/20 | 0.93 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874080 | 1.00 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9ATDP1 | |
| SCHEMBL14634632 | 1.00 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9ATDP1 | |
| Sergliflozin Etabonate SCHEMBL18058588 | 0.96 | SLC5A2 (1.00) | SLC5A2SLC5A1NPC1RAB9A | |
| Sergliflozin Etabonate SCHEMBL8018797 | 0.96 | SLC5A2 (1.00) | SLC5A2SLC5A1NPC1RAB9A | |
| Sergliflozin Etabonate SCHEMBL16421550 | 0.96 | SLC5A2 (1.00) | SLC5A2SLC5A1NPC1RAB9A | |
| Sergliflozin Etabonate SCHEMBL23731198 | 0.96 | SLC5A2 (1.00) | SLC5A2SLC5A1NPC1RAB9A | |
| Sergliflozin Etabonate SCHEMBL621807 | 0.96 | SLC5A2 (1.00) | SLC5A2SLC5A1NPC1RAB9A | |
| Sergliflozin Etabonate SCHEMBL621808 | 0.96 | SLC5A2 (1.00) | SLC5A2SLC5A1NPC1RAB9A | |
| Sergliflozin Etabonate SCHEMBL15827906 | 0.96 | SLC5A2 (1.00) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL4360297 | 0.96 | SLC5A2 (0.86) | SLC5A2SLC5A1NPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100071-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2024-03-28 | — | — | US | claimed |
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | INCREVET, INC. | 2023-01-05 | — | — | US | claimed |
| EP-4023218-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-Form Pharma (BE) | 2022-07-06 | — | — | EP | claimed |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | claimed |
| EP-3323818-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | claimed |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | claimed |
| US-20240100071-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2024-03-28 | — | — | US | disclosed |
| US-11813274-B2 | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2023-11-14 | — | — | US | disclosed |
| US-20230201174-A1 | COMBINATION OF FINERENONE AND A SGLT2 INHIBITOR FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR AND/OR RENAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| EP-4138826-A1 | COMBINATION OF FINERENONE AND A SGLT2 INHIBITOR FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR AND/OR RENAL DISEASES | Bayer Aktiengesellschaft (DE) | 2023-03-01 | — | — | EP | disclosed |
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | INCREVET, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-4023218-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-Form Pharma (BE) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | disclosed |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20130317005-A1 | NON-HYGROSCOPIC SALTS OF 5-HT2C AGONISTS | Arena Pharmaceuticals ,Inc | 2013-11-28 | — | — | US | disclosed |
| US-20130315994-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. | 2013-11-28 | — | — | US | disclosed |
| US-20130310369-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | ARENA PHARMACEUTICALS, INC | 2013-11-21 | — | — | US | disclosed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | SLC5A2 4/4885SLC5A1 5/4885NPC1 696/4885 |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | SLC5A2 2/4885SLC5A1 3/4885NPC1 313/4885 |
| US-20130315994-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | HTR2C, HTR2A, HTR3C | SLC5A2 60/4885SLC5A1 118/4885NPC1 1936/4885 |
| US-11813274-B2 | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885SLC5A1 2/4885NPC1 927/4885 |
| US-20130310369-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | CEL, HTR7, HTR1A | SLC5A2 71/4885SLC5A1 46/4885NPC1 673/4885 |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, DPP4 | SLC5A2 4/4885SLC5A1 5/4885NPC1 460/4885 |
| US-20230201174-A1 | COMBINATION OF FINERENONE AND A SGLT2 INHIBITOR FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR AND/OR RENAL DISEASES | SLC5A2, SLC5A1, REN | SLC5A2 1/4885SLC5A1 2/4885NPC1 451/4885 |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | SLC5A2 4/4885SLC5A1 5/4885NPC1 732/4885 |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | GPR119, GLP1R, DPP9 | SLC5A2 4/4885SLC5A1 6/4885NPC1 427/4885 |
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885NPC1 284/4885 |
| US-20130317005-A1 | NON-HYGROSCOPIC SALTS OF 5-HT2C AGONISTS | HTR2C, HTR2A, HTR1A | SLC5A2 120/4885SLC5A1 236/4885NPC1 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.